Predictive significance of the serum p53 antibody status in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.

Trial Profile

Predictive significance of the serum p53 antibody status in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top